Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation.
aging
female reproductive endocrinology
gonadotropins
inhibin/activin/follistatin/AMH
menopause
ovaries
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
09
09
2019
accepted:
16
12
2019
pubmed:
23
1
2020
medline:
5
1
2021
entrez:
23
1
2020
Statut:
ppublish
Résumé
A test that helps predict the time to the final menstrual period (FMP) has been sought for many years. To assess the ability of antimullerian hormone (AMH) measurements to predictions the time to FMP. Prospective longitudinal cohort study. The Study of Women's Health Across the Nation. AMH and FSH were measured in 1537 pre- or early perimenopausal women, mean age 47.5 ± 2.6 years at baseline, then serially until 12 months of amenorrhea occurred. AMH was measured using a 2-site ELISA with a detection limit of 1.85 pg/mL. Areas under the receiver operating curves (AUC) for AMH-based and FSH-based predictions of time to FMP, stratified by age. Probabilities that women would undergo their FMP in the next 12, 24, or 36 months across a range of AMH values were assessed. AUCs for predicting that the FMP will occur within the next 24 months were significantly greater for AMH-based than FSH-based models. The probability that a woman with an AMH <10 pg/mL would undergo her FMP within the next 12 months ranged from 51% at h<48 years of age to 79% at ≥51 years. The probability that a woman with an AMH >100 pg/mL would not undergo her FMP within the next 12 months ranged from 97% in women <48 years old to 90% in women ≥51 years old. AMH measurement helps estimate when a woman will undergo her FMP, and, in general, does so better than FSH.
Sections du résumé
BACKGROUND
A test that helps predict the time to the final menstrual period (FMP) has been sought for many years.
OBJECTIVE
To assess the ability of antimullerian hormone (AMH) measurements to predictions the time to FMP.
DESIGN
Prospective longitudinal cohort study.
SETTING
The Study of Women's Health Across the Nation.
PARTICIPANTS AND MEASUREMENTS
AMH and FSH were measured in 1537 pre- or early perimenopausal women, mean age 47.5 ± 2.6 years at baseline, then serially until 12 months of amenorrhea occurred. AMH was measured using a 2-site ELISA with a detection limit of 1.85 pg/mL.
MAIN OUTCOME MEASURE
Areas under the receiver operating curves (AUC) for AMH-based and FSH-based predictions of time to FMP, stratified by age. Probabilities that women would undergo their FMP in the next 12, 24, or 36 months across a range of AMH values were assessed.
RESULTS
AUCs for predicting that the FMP will occur within the next 24 months were significantly greater for AMH-based than FSH-based models. The probability that a woman with an AMH <10 pg/mL would undergo her FMP within the next 12 months ranged from 51% at h<48 years of age to 79% at ≥51 years. The probability that a woman with an AMH >100 pg/mL would not undergo her FMP within the next 12 months ranged from 97% in women <48 years old to 90% in women ≥51 years old.
CONCLUSIONS
AMH measurement helps estimate when a woman will undergo her FMP, and, in general, does so better than FSH.
Identifiants
pubmed: 31965189
pii: 5709648
doi: 10.1210/clinem/dgz283
pmc: PMC7067546
pii:
doi:
Substances chimiques
Biomarkers
0
Anti-Mullerian Hormone
80497-65-0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIA NIH HHS
ID : U01 AG012554
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012505
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG017719
Pays : United States
Organisme : NIOSH CDC HHS
ID : T42 OH008455
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012495
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012535
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012553
Pays : United States
Organisme : NINR NIH HHS
ID : U01 NR004061
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012539
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012546
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
JAMA Cardiol. 2016 Oct 1;1(7):767-776
pubmed: 27627190
J Clin Endocrinol Metab. 2003 Nov;88(11):5502-9
pubmed: 14602797
J Assist Reprod Genet. 2000 Mar;17(3):168-73
pubmed: 10911578
Menopause. 2016 Aug;23(8):884-7
pubmed: 27272224
J Clin Endocrinol Metab. 2012 May;97(5):1673-80
pubmed: 22378815
Fertil Steril. 2002 Feb;77(2):357-62
pubmed: 11821097
Reprod Sci. 2016 Jun;23(6):756-60
pubmed: 26614267
J Clin Endocrinol Metab. 2008 Mar;93(3):861-8
pubmed: 18160467
J Clin Endocrinol Metab. 1990 Jan;70(1):11-5
pubmed: 2403569
Fertil Steril. 2007 Sep;88(3):539-46
pubmed: 17559842
Fertil Steril. 2012 Nov;98(5):1254-9.e1-2
pubmed: 22921911
Clin Chem. 2002 Sep;48(9):1584-6
pubmed: 12194939
Fertil Steril. 2002 Mar;77(3):468-71
pubmed: 11872196
Epidemiology. 2005 Jul;16(4):556-62
pubmed: 15951675
Climacteric. 2002 Mar;5(1):92
pubmed: 11974565
Am J Public Health. 1993 Jul;83(7):983-8
pubmed: 8328621
J Clin Endocrinol Metab. 2006 Oct;91(10):4057-63
pubmed: 16804046
J Epidemiol. 2006 Sep;16(5):177-84
pubmed: 16951536
JAMA. 2003 Feb 19;289(7):895-902
pubmed: 12588275
Cell. 1986 Jun 6;45(5):685-98
pubmed: 3754790
Hum Reprod. 2006 Dec;21(12):3103-7
pubmed: 16923748
JAMA. 2017 Oct 10;318(14):1367-1376
pubmed: 29049585
J Clin Endocrinol Metab. 2008 Sep;93(9):3478-83
pubmed: 18593767
Am J Obstet Gynecol. 1979 Dec 15;135(8):1021-4
pubmed: 517585
Lancet Oncol. 2012 Nov;13(11):1141-51
pubmed: 23084519
Endocrinology. 2006 Jul;147(7):3228-34
pubmed: 16556768
Mol Hum Reprod. 2004 Feb;10(2):77-83
pubmed: 14742691
J Clin Endocrinol Metab. 1996 Feb;81(2):571-6
pubmed: 8636269
Menopause. 2014 Dec;21(12):1277-86
pubmed: 24781853
Am J Epidemiol. 2003 May 15;157(10):923-9
pubmed: 12746245
Maturitas. 2017 Aug;102:18-25
pubmed: 28610678
Hum Reprod. 2002 Dec;17(12):3065-71
pubmed: 12456604
Semin Reprod Med. 2004 Aug;22(3):209-17
pubmed: 15319823
Biomark Insights. 2008 Apr 16;3:259-268
pubmed: 19578510
Arch Intern Med. 1999 May 24;159(10):1061-6
pubmed: 10335682
JAMA Intern Med. 2015 Apr;175(4):531-9
pubmed: 25686030
J Clin Endocrinol Metab. 2011 Aug;96(8):2532-9
pubmed: 21613357
J Clin Endocrinol Metab. 1990 Jan;70(1):23-7
pubmed: 1688440
Science. 2002 May 10;296(5570):1029-31
pubmed: 12004104
Hum Reprod. 2014 Aug;29(8):1764-72
pubmed: 24925522
J Clin Endocrinol Metab. 1990 Jan;70(1):16-22
pubmed: 2294129
Fertil Steril. 2002 Nov;78(5):1046-8
pubmed: 12413991
Hum Reprod. 2014 Dec;29(12):2764-72
pubmed: 25336708
J Clin Endocrinol Metab. 2013 Apr;98(4):1483-91
pubmed: 23533245
Epidemiol Rev. 1993;15(1):36-47
pubmed: 8405211
Am J Epidemiol. 2001 May 1;153(9):865-74
pubmed: 11323317
Menopause. 2007 May-Jun;14(3 Pt 1):415-24
pubmed: 17303963
Menopause. 2004 Nov-Dec;11(6 Pt 1):601-6
pubmed: 15545787
J Clin Endocrinol Metab. 2006 Aug;91(8):3034-40
pubmed: 16720656
PLoS One. 2011;6(7):e22024
pubmed: 21789206
Maturitas. 2015 Aug;81(4):493-8
pubmed: 26139426
Am J Epidemiol. 2013 Jul 1;178(1):70-83
pubmed: 23788671
Menopause. 2011 Jul;18(7):766-70
pubmed: 21451424
Fertil Steril. 2010 Sep;94(4):1482-6
pubmed: 19969291
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Clin Endocrinol Metab. 2006 Sep;91(9):3432-8
pubmed: 16772350